Seminars in Hematology
Volume 43, Issue 1 , Pages 3-10, January 2006

Pathophysiology of Graft-Versus-Host Disease

  • James L.M. Ferrara

      Affiliations

    • Corresponding Author InformationAddress correspondence to James L.M. Ferrara, MD, Professor of Pediatrics and Medicine, University of Michigan Medical School, 1500 E Medical Center Dr, 6308 CCGC, Ann Arbor, MI 48109-0942.
  • ,
  • Pavan Reddy

University of Michigan Medical School, Ann Arbor, MI.

Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality following allogeneic HSCT. GVHD can be considered an exaggerated, undesirable manifestation of a normal inflammatory mechanism, in which donor lymphocytes encounter foreign antigens in a milieu that fosters inflammation. Recent advances in the study of cytokine networks, chemokine gradients, and the direct mediators of cellular cytotoxicity have led to improved understanding of this complex syndrome. The pathophysiology of acute GVHD can be considered as a three-step process in which the innate and adaptive immune systems interact: (1) tissue damage to the recipient by the radiation/chemotherapy pretransplant conditioning regimen; (2) donor T-cell activation and clonal expansion; and (3) cellular and inflammatory factors. Here we review the immunologic interactions that cause clinical GVHD and discuss the risk factors and prophylactic strategies for acute GVHD according to this model.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by National Institutes of Health Grants No. K08 AI052863-01 (P.R.) and PO1 CA 49542 (J.L.M.F.). P.R. is the recipient of the Alaina J. Enlow Scholar Award from Amy Strelzer Manasevit-National Marrow Donor Program and the New Investigator Award from American Society of Blood and Marrow Transplantation. J.L.M.F. is the recipient of the Doris Duke Distinguished Clinical Scientist Award.

PII: S0037-1963(05)00166-6

doi:10.1053/j.seminhematol.2005.09.001

Seminars in Hematology
Volume 43, Issue 1 , Pages 3-10, January 2006